XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 8.65%55.48B | 24.30%14.59B | 29.95%15.76B | -1.67%12.77B | -13.04%12.36B | -37.37%51.07B | -34.11%11.74B | -46.73%12.13B | -40.01%12.99B | -26.36%14.21B |
Operating revenue | 8.65%55.48B | 24.30%14.59B | 29.95%15.76B | -1.67%12.77B | -13.04%12.36B | -37.37%51.07B | -34.11%11.74B | -46.73%12.13B | -40.01%12.99B | -26.36%14.21B |
Cost of revenue | 2.91%48.56B | -6.01%47.19B | ||||||||
Gross profit | 78.60%6.92B | -87.63%3.87B | ||||||||
Operating expense | 13.81%956M | 31.66%840M | ||||||||
Other operating expenses | 23.53%21M | ---- | ---- | ---- | ---- | -88.89%17M | ---- | ---- | ---- | ---- |
Operating profit | 96.54%5.96B | -90.11%3.03B | ||||||||
Net non-operating interest income expense | -50.58%213M | 230.61%431M | ||||||||
Non-operating interest income | -7.65%1.11B | ---- | ---- | ---- | ---- | 175.69%1.2B | ---- | ---- | ---- | ---- |
Non-operating interest expense | 16.34%897M | ---- | ---- | ---- | ---- | 0.65%771M | ---- | ---- | ---- | ---- |
Other net income (expense) | ||||||||||
Special income (charges) | -67.05%173M | ---- | ---- | ---- | ---- | 1,358.33%525M | ---- | ---- | ---- | ---- |
-Less:Restructuring and merger&acquisition | 812.50%57M | ---- | ---- | ---- | ---- | -114.81%-8M | ---- | ---- | ---- | ---- |
-Less:Other special charges | 57.55%-222M | ---- | ---- | ---- | ---- | -417.82%-523M | ---- | ---- | ---- | ---- |
-Write off | -233.33%-8M | ---- | ---- | ---- | ---- | -45.45%6M | ---- | ---- | ---- | ---- |
Income before tax | 56.26%6.82B | 616.97%2.25B | 371.49%3.26B | -38.65%976M | -86.96%328M | -85.57%4.36B | -108.24%-436M | -92.47%691M | -81.89%1.59B | -63.95%2.52B |
Income tax | 28.63%584M | 620.00%144M | 29.20%177M | 37.50%143M | -37.82%120M | -50.11%454M | -93.59%20M | -47.91%137M | -36.59%104M | 12.87%193M |
Net income | 59.47%6.23B | 562.72%2.11B | 456.14%3.08B | -43.98%833M | -91.05%208M | -86.67%3.91B | -109.15%-456M | -93.78%554M | -82.75%1.49B | -65.88%2.32B |
Net income continuous Operations | 59.47%6.23B | 562.72%2.11B | 456.14%3.08B | -43.98%833M | -91.05%208M | -86.67%3.91B | -109.15%-456M | -93.78%554M | -82.75%1.49B | -65.88%2.32B |
Minority interest income | 43.02%123M | 225.00%25M | -3.03%32M | 2.94%35M | -20.51%31M | -30.08%86M | -164.52%-20M | 3.13%33M | 21.43%34M | 21.88%39M |
Net income attributable to the parent company | 59.84%6.11B | 578.21%2.09B | 485.22%3.05B | -45.08%798M | -92.25%177M | -86.91%3.82B | -108.81%-436M | -94.13%521M | -83.09%1.45B | -66.29%2.28B |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 59.84%6.11B | 578.21%2.09B | 485.22%3.05B | -45.08%798M | -92.25%177M | -86.91%3.82B | -108.81%-436M | -94.13%521M | -83.09%1.45B | -66.29%2.28B |
Basic earnings per share | 70.48%1.935 | 673.91%0.66 | 522.58%0.965 | -40.00%0.255 | -91.60%0.055 | -85.81%1.135 | -108.16%-0.115 | -93.65%0.155 | -81.76%0.425 | -64.01%0.655 |
Diluted earnings per share | 70.48%1.935 | 673.91%0.66 | 522.58%0.965 | -40.00%0.255 | -91.60%0.055 | -85.77%1.135 | -108.16%-0.115 | -93.63%0.155 | -81.68%0.425 | -63.91%0.655 |
Dividend per share | -51.49%0.7081 | 0 | 0 | 0.3339 | -74.36%0.3743 | -21.13%1.4598 | 0 | 0 | 0 | -21.13%1.4598 |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |